Pretreatment of trans-ferulic acid improved neurotoxicity in a thioacetamide-induced hepatic encephalopathy rat model; participation of the MAPK/NF-κb signaling pathway

ArticleAçık Erişim

Özet

Aim – Trans-ferulic acid (TFA), a naturally occurring phenolic compound, has attracted significant attention due to its strong hepatoprotective and neuroprotective properties. Despite extensive research on its overall biological activities, the specific mechanisms by which TFA influences hepatic encephalopathy (HE) remain unclear. This study aims to explore the therapeutic potential of TFA by examining its effects on inflammatory signaling, glial activation, and apoptotic pathways in a thioacetamide (TAA)-induced rat model of HE. Methods – Rats were separated into four groups: a normal control group, the TAA group (which received TAA at 300 mg/kg/day for 3 days), and groups pre-treated with TFA (at doses of 25/50 mg/kg, administered orally) for 10 days, with TAA administered from the eighth to the 10th day. Results – TFA pre-treatment effectively reduced TAA-induced biochemical disturbances, as shown by lower serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and ammonia. This biochemical improvement was complemented by a significant reduction in TAA-related hepatic histopathological damage. TFA also alleviated systemic inflammation by suppressing TAA-induced increases in pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), while also elevating the anti-inflammatory cytokine IL-10. Consistent with these results, TFA further suppressed the activation of MAPK/NF-κB inflammatory signaling pathways in both liver and brain tissues and decreased glial fibrillary acidic protein (GFAP) expression in the brains of TAA-treated rats, indicating reduced neuroinflammation and astrocyte activation. Additionally, immunochemical analysis showed that TFA pre-treatment effectively prevented the TAA-induced increase in pro-apoptotic markers Caspase-3 and Bax in both liver and brain tissues. This study underscores the strong protective effects of TFA against TAA-induced HE, mainly through inhibition of MAPK/NF-κB signaling, suppression of astrocyte activation, and reduction of apoptosis. Conclusion – These outcomes imply that TFA could be an effective treatment for HE. Copyright © 2026 Kilic, Suleyman, Mammadov, Bulut, Mendil and Suleyman.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/10125Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.3389/fphar.2026.1750709Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorKilic, Adil Furkan
dc.contributor.authorSuleyman, Bahadir
dc.contributor.authorMammadov, Renad
dc.contributor.authorBulut, Seval
dc.contributor.authorMendil, Ali Sefa
dc.contributor.authorSuleyman, Halis
dc.date.accessioned2026-10-18T20:25:22.820087821Z
dc.date.available2026-10-18T20:25:22.820087821Z
dc.date.issued2026
dc.description.abstractAim – Trans-ferulic acid (TFA), a naturally occurring phenolic compound, has attracted significant attention due to its strong hepatoprotective and neuroprotective properties. Despite extensive research on its overall biological activities, the specific mechanisms by which TFA influences hepatic encephalopathy (HE) remain unclear. This study aims to explore the therapeutic potential of TFA by examining its effects on inflammatory signaling, glial activation, and apoptotic pathways in a thioacetamide (TAA)-induced rat model of HE. Methods – Rats were separated into four groups: a normal control group, the TAA group (which received TAA at 300 mg/kg/day for 3 days), and groups pre-treated with TFA (at doses of 25/50 mg/kg, administered orally) for 10 days, with TAA administered from the eighth to the 10th day. Results – TFA pre-treatment effectively reduced TAA-induced biochemical disturbances, as shown by lower serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and ammonia. This biochemical improvement was complemented by a significant reduction in TAA-related hepatic histopathological damage. TFA also alleviated systemic inflammation by suppressing TAA-induced increases in pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), while also elevating the anti-inflammatory cytokine IL-10. Consistent with these results, TFA further suppressed the activation of MAPK/NF-κB inflammatory signaling pathways in both liver and brain tissues and decreased glial fibrillary acidic protein (GFAP) expression in the brains of TAA-treated rats, indicating reduced neuroinflammation and astrocyte activation. Additionally, immunochemical analysis showed that TFA pre-treatment effectively prevented the TAA-induced increase in pro-apoptotic markers Caspase-3 and Bax in both liver and brain tissues. This study underscores the strong protective effects of TFA against TAA-induced HE, mainly through inhibition of MAPK/NF-κB signaling, suppression of astrocyte activation, and reduction of apoptosis. Conclusion – These outcomes imply that TFA could be an effective treatment for HE. Copyright © 2026 Kilic, Suleyman, Mammadov, Bulut, Mendil and Suleyman.
dc.identifier.doi10.3389/fphar.2026.1750709
dc.identifier.eissn1663-9812
dc.identifier.issn1663-9812
dc.identifier.pmcidPMC13233277
dc.identifier.pmid42256411
dc.identifier.scopus2-s2.0-105043273515
dc.identifier.startpage1750709
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/10125
dc.identifier.volume17
dc.identifier.wosWOS:001783544200001
dc.language.isoen
dc.publisherFrontiers Media SA
dc.relation.ispartofFrontiers in Pharmacology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjecthepatic encephalopathy
dc.subjectMAPK/NF-κB
dc.subjectrats
dc.subjectthioacetamide
dc.subjecttrans-ferulic acid
dc.subjectalanine aminotransferase
dc.subjectalkaline phosphatase
dc.subjectammonia
dc.subjectaspartate aminotransferase
dc.subjectcarboxymethylcellulose
dc.subjectcaspase 3
dc.subjectferulic acid
dc.subjectinterleukin 10
dc.subjectinterleukin 6
dc.subjectpentobarbital
dc.subjectprotein Bax
dc.subjectsodium chloride
dc.subjecttrans ferulic acid
dc.subjecttumor necrosis factor
dc.subjectunclassified drug
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectArticle
dc.subjectastrocyte
dc.subjectbiochemical analysis
dc.subjectblood sampling
dc.subjectbrain tissue
dc.subjectcognition
dc.subjectcontrolled study
dc.titlePretreatment of trans-ferulic acid improved neurotoxicity in a thioacetamide-induced hepatic encephalopathy rat model; participation of the MAPK/NF-κb signaling pathway
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus1
rdl.citation.wos1
rdl.departmentDepartment of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Türkiye.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)